L-acetylcarnitine for fragile X syndrome

  • Protocol
  • Intervention

Authors

  • José-Ramón Rueda,

    Corresponding author
    1. University of the Basque Country, Department of Preventive Medicine and Public Health, Leioa, Bizkaia, Spain
    • José-Ramón Rueda, Department of Preventive Medicine and Public Health, University of the Basque Country, GIU 10/24, UPV-EHU, Leioa, Bizkaia, E-48080, Spain. joseramon.rueda@ehu.es.

    Search for more papers by this author
  • Virginia Guillén,

    1. University of the Basque Country, Department of Neuroscience, Leioa, Spain
    Search for more papers by this author
  • Javier Ballesteros,

    1. University of the Basque Country, Department of Neuroscience, Leioa, Spain
    2. University of the Basque Country, Centre for Biomedical Research Network on Mental Health (CIBERSAM), Leioa, Spain
    Search for more papers by this author
  • Maria-Isabel Tejada,

    1. Hospital Universitario Cruces, Molecular Genetics Laboratory, Department of Biochemistry, Barakaldo, Bizkaia, Spain
    Search for more papers by this author
  • Ivan Solà

    1. Institute of Biomedical Research (IIB Sant Pau), Iberoamerican Cochrane Centre, Barcelona, Catalunya, Spain
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To review the efficacy and safety of L-acetylcarnitine in the treatment of people with fragile X syndrome.